Pancreatic Insufficiency Clinical Trial
Official title:
Analysis of Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH) Cohort Using Advanced MRI to Characterize and Predict CF Liver Disease
Verified date | October 2023 |
Source | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Specific Aim 1. Determine if valid results of non-sedated MRI based assessments of liver stiffness and lipid content can be obtained in more than 90% of children and young adults with cystic fibrosis. Specific Aim 2. Determine hepatic lipid content using the HepaFat sequence and liver stiffness using MRE. Investigators will compare the results obtained by MRI with PUSH study grayscale ultrasounds in CF patients with normal, heterogeneous, homogeneous or nodular (cirrhotic) pattern on ultrasound. Specific Aim 3. Creation of an imaging core lab to centralize evaluation of MR imaging data, allow for remote image upload, electronic data storage, and remote image viewing/interpretation. This infrastructure will be utilized to standardize image post processing. Specific Aim 4. Using the longitudinal PUSH study, determine if MRI based imaging improves discrimination of subjects at risk for progression to advanced CF liver disease (development of cirrhosis) compared to using US imaging alone
Status | Completed |
Enrollment | 115 |
Est. completion date | December 27, 2019 |
Est. primary completion date | December 27, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 26 Years |
Eligibility | Inclusion Criteria: 1. Currently enrolled in longitudinal follow up in PUSH study at a site with MR elastography. Exclusion Criteria: 1. Age under 6 years (all current patients at time of opening of this study will be greater than 6 years of age). 2. Internal appliance or hardware that is not compatible with MR. 3. Inability to obtain MRI within 6 months of US. 4. Inability to cooperate with MRI. |
Country | Name | City | State |
---|---|---|---|
United States | Children's Healthcare of Atlanta | Atlanta | Georgia |
United States | Children's Hospital Colorado | Aurora | Colorado |
United States | Johns Hopkins School of Medicine | Baltimore | Maryland |
United States | Cincinnati Children's Hospital Medical | Cincinnati | Ohio |
United States | Texas Children's Hospital | Houston | Texas |
United States | Riley Hospital for Children | Indianapolis | Indiana |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | Seattle Children's Hospital | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Cystic Fibrosis Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change over Time in Liver stiffness and Lipid content over time using MRE | Analysis of variance (ANOVA) will be used to compare the distribution of liver stiffness (in kPa) and lipid content measures between all groups defined by PUSH study grayscale ultrasounds results over time. | BSL, Year 1, Year 2 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03279653 -
Pancreatic Exocrine Insufficiency After Bariatric Surgery
|
N/A | |
Completed |
NCT00763412 -
Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT01851694 -
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
|
N/A | |
Completed |
NCT01710644 -
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
|
Phase 1/Phase 2 | |
Completed |
NCT01988350 -
Pancreatic Insufficiency Secondary to Tobacco Exposure
|
N/A | |
Active, not recruiting |
NCT01012908 -
Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency
|
Phase 2/Phase 3 | |
Completed |
NCT01879228 -
Effect of Chronic Incretin-based Therapy in Cystic Fibrosis
|
N/A | |
Completed |
NCT00705978 -
Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis
|
Phase 3 | |
Completed |
NCT00095732 -
Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency
|
Phase 2 | |
Completed |
NCT00513682 -
Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)
|
Phase 3 | |
Recruiting |
NCT05466838 -
PERT to Improve Quality of Life in Patients Undergoing Pancreaticoduodenectomy: A Pilot Randomized Controlled Trial
|
N/A | |
Completed |
NCT00432861 -
Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis
|
Phase 3 | |
Completed |
NCT00406536 -
Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI
|
Phase 2 | |
Completed |
NCT01144507 -
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
|
||
Completed |
NCT05700604 -
Hypoglycemia and Glucagon Response in CF
|
||
Terminated |
NCT02985801 -
PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03551691 -
Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)
|
Phase 2 | |
Recruiting |
NCT03450772 -
Equivalence Study to Compare Two Strengths of Creon in China
|
Phase 3 | |
Completed |
NCT00572975 -
Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea
|
Phase 4 | |
Completed |
NCT00880100 -
Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)
|
Phase 3 |